Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Ref Type
Authors Olivier Rixe, John Charles Morris, Vinay K. Puduvalli, John L. Villano, Trisha Michel Wise-Draper, Carolyn Muller, Angela N. Johnson, Robert Wesolowski, Xiaoyang Qi
Title First-in-human, first-in-class phase 1a study of BXQ-350 for solid tumors and gliomas.
Journal Journal of Clinical Oncology
Abstract Text Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 2517-2517


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
BXQ-350 BXQ-350 1 3
Drug Name Trade Name Synonyms Drug Classes Drug Description
BXQ-350 SapC-DOPS SapC-DOPS (BXQ-350) is a nanovesicle of saposin C (SapC; a lysosomal protein) and dioleylphosphatidylserine (DOPS) that targets phosphatidylserine to activate lysosomes resulting in apoptosis in cells with high surface levels of phosphatidylserine (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 2517-2517, PMID: 31918715).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable BXQ-350 Phase I Actionable In a Phase I trial, BXQ-350 demonstrated safety and preliminary efficacy, resulted in partial response in 6% (1/17) and stable disease in 35% (6/17) of patients with advanced solid tumors (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 2517-2517; NCT02859857). detail...